Drug Type Small molecule drug |
Synonyms KBP 5074, KBP-5074 |
Target |
Mechanism MR antagonists(Mineralocorticoid receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H30ClN5O2 |
InChIKeyUXHQLGLGLZKHTC-CUNXSJBXSA-N |
CAS Registry1359969-24-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Kidney Diseases | Phase 3 | US | 05 Nov 2021 | |
Chronic Kidney Diseases | Phase 3 | CN | 05 Nov 2021 | |
Chronic Kidney Diseases | Phase 3 | AU | 05 Nov 2021 | |
Chronic Kidney Diseases | Phase 3 | BA | 05 Nov 2021 | |
Chronic Kidney Diseases | Phase 3 | BG | 05 Nov 2021 | |
Chronic Kidney Diseases | Phase 3 | CA | 05 Nov 2021 | |
Chronic Kidney Diseases | Phase 3 | HR | 05 Nov 2021 | |
Chronic Kidney Diseases | Phase 3 | CZ | 05 Nov 2021 | |
Chronic Kidney Diseases | Phase 3 | GE | 05 Nov 2021 | |
Chronic Kidney Diseases | Phase 3 | DE | 05 Nov 2021 |
Phase 3 | 600 | mhsgdpurlr(tbtwxieonu) = failed to meet its primary endpoint guszjffkva (ivpnrkslra ) Not Met | Negative | 27 Jun 2024 | |||
Not Applicable | - | pixenkfmcv(wqqljqjaxm) = varokjztob vbfxuhebro (dcgozhloyl ) View more | Positive | 04 Nov 2022 | |||
pixenkfmcv(wqqljqjaxm) = kboqpyqswu vbfxuhebro (dcgozhloyl ) View more | |||||||
Phase 2 | 162 | Placebo | bpiulojnbb(qgxdrwnwwi) = xryhqmwwnq obywuayfrl (tjbwiqmuhy ) | Positive | 10 May 2021 | ||
bpiulojnbb(qgxdrwnwwi) = sftikmpzrq obywuayfrl (tjbwiqmuhy ) | |||||||
Phase 1 | 11 | rqglnohfpn(qmeacxieol) = xdqljydafs jmxhohhjge (csspgwhqqa, zskamtgeqq - akyzzothit) View more | - | 15 Oct 2019 | |||
Phase 1 | 11 | ilzanhmfik(svsexczuba) = xukziwgpjv tsrinzwzfl (heysvpesdu ) View more | Positive | 31 Oct 2017 | |||
ilzanhmfik(svsexczuba) = fpybpqqfgl tsrinzwzfl (heysvpesdu ) View more | |||||||
Not Applicable | 14 | udfmnjsotc(zgmuqkbtua) = 2 subjects in the 2.5 mg group developed hyperkalemia (serum potassium >5.5 mmol/L); 1 subject in the 0.5 mg group with baseline serum potassium 5.0 mmol/L also developed hyperkalemia on study. These three subjects continued in the study. There were no study drug-related serious adverse events or deaths in this study. njfryddluj (btjppbttii ) | Positive | 15 Nov 2016 | |||